The vector of anti-GPC3 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human GPC3. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-GPC3 antibody linked to CD3-zeta and b2c signaling domains. And the vector product was designed for the treatment of hepatocellular carcinoma (HCC).
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|OAdCmodV-YX1240||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/19k, Anti-GPC3-3), Viral particle|
|VP-CAR-LC579||Lenti-GPC3 CAR (scFv-CD28-CD3ζ) Viral Particle|
|VP-CAR-LC663||Lenti-GPC3 CAR (scFv-CD28-41BB-CD3ζ, 3E11) Viral Particle|
|OAdCmodV-YX1262||Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ19k, Anti-GPC3-1), Viral particle|
|VP-TCR-C173||Lenti-GPC3 T cell receptor (P2-1) Viral Particle|
|CAR-T-2-L342-2G||Anti-GPC3 scFv h(CD28-FcεRIγ) CART, pCDCAR1|
|OAdCmodV-YX1241||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/55k, Anti-GPC3), Viral particle|
|CAR-LC091||Anti-GPC3 h(CD28-CD3ζ) CAR, pCDCAR1|
|CAR-LC090||Anti-GPC3 h(CD3ζ) CAR, pCDCAR1|
|OAdCmodV-YX1243||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/55k, Anti-GPC3-2), Viral particle|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved